Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration's (FDA) drug shortage list nearly four months after the agency found the drugs to be available.

The FDA's drug shortage list now states that as of Feb. 21, 2025, the shortages of Ozempic and Wegovy injections are over. The shortages were first declared in August of 2022.

At the end of October, the FDA had determined that there was an available supply of both drugs and that they were no longer "currently in shortage." This occurred shortly after the shortages of Mounjaro and Zepbound had been declared over, setting off concerted pushback from compounding pharmacy groups who were able to sell copycat versions of the drugs while they were in shortage.

Novo Nordisk, the manufacturer of semaglutide, confirmed in a statement Friday that the........

© The Hill